Premium
Thymalfasin for the Treatment of Chronic Hepatitis C Infection
Author(s) -
RUSTGI VINOD K.
Publication year - 2007
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1415.034
Subject(s) - ribavirin , medicine , placebo , hepatitis c virus , gastroenterology , interferon , virology , hepatitis c , chronic hepatitis , viral load , combination therapy , genotype , virus , immunology , biology , pathology , biochemistry , alternative medicine , gene
: The purpose of this review article is to examine previous and ongoing studies of thymalfasin in combination with peginterferon‐α2a and peginterferon‐α2a plus ribavirin in difficult‐to‐treat hepatitis C virus ( HCV) patients. The following studies will be reviewed in detail: (1) Sherman and colleagues conducted a study in 109 HCV RNA positive HVC patients comparing the combination of thymalfasin + IFN versus IFN alone versus placebo. (2) Rustgi et al . evaluated the efficacy and safety of thymalfasin and peg‐IFN‐α2a in 31 genotype 1, high viral load, HCV nonresponders in a 12‐week viral kinetic study. (3) Di Bisceglie, Sherman et al . performed a study of previous HCV nonresponders being retreated with either peginterferon‐α2a plus thymalfasin or peginterferon‐α2a plus placebo. (4) Poo and colleagues in Mexico evaluated triple combination therapy using thymalfasin, peginterferon‐α2a, and ribavirin for the treatment of Hispanic HCV nonresponders.